U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Topspins, Inc. - 01/11/2017
  1. Warning Letters

CLOSEOUT LETTER

Topspins, Inc.

Recipient:
Topspins, Inc.

United States

Issuing Office:

United States

  

Department of Health and Human Services logoDepartment of Health and Human Services

Public Health Service
Food and Drug Administration
 Detroit District
300 River Place
Suite 5900
Detroit, Ml 48207
Telephone: 313-393-8100
FAX: 313-393-8139 

 

January 11, 2017

VIA UPS

Martin R. Prince, MD
President
Topspins, Inc.
403 Riverview Drive
Ann Arbor, MI 48104-1849

Dear Dr. Prince:

The Food and Drug Administration has completed an evaluation of your firm's corrective actions in response to our Warning Letter [2015-DET-01, dated November 6, 2014]. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,

/S/

Catherine V. Quinlan
Compliance Officer
Detroit District

Back to Top